Elite Pharmaceuticals Inc (ELTP) stock
ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –
Elite Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Elite Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was 40.2%. For fiscal 2026 it was 30.1%, against -5.1% the year before. The highest annual figure on record is 104.1% in fiscal 2015.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | 30.1% | +35.3 |
| FY2025 | Mar 31, 2025 | -5.1% | −40.6 |
| FY2024 | Mar 31, 2024 | 35.5% | +25.1 |
| FY2023 | Mar 31, 2023 | 10.4% | −17.2 |
| FY2022 | Mar 31, 2022 | 27.6% | +7.5 |
| FY2021 | Mar 31, 2021 | 20.0% | +32.5 |
| FY2020 | Mar 31, 2020 | -12.5% | +110.2 |
| FY2019 | Mar 31, 2019 | -122.6% | −73.4 |
| FY2018 | Mar 31, 2018 | -49.2% | −88.8 |
| FY2017 | Mar 31, 2017 | 39.5% | +45.0 |
| FY2016 | Mar 31, 2016 | -5.5% | −109.6 |
| FY2015 | Mar 31, 2015 | 104.1% | +1000.8 |
| FY2014 | Mar 31, 2014 | -896.7% | −940.4 |
| FY2013 | Mar 31, 2013 | 43.7% | +664.9 |
| FY2012 | Mar 31, 2012 | -621.2% | −302.8 |
| FY2011 | Mar 31, 2011 | -318.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | 18.3% | +32.9 |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | 45.3% | −7.8 |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | 58.9% | +134.7 |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | 37.7% | +96.2 |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -14.6% | −17.9 |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | 53.1% | +34.6 |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -75.8% | −80.4 |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -58.5% | −163.9 |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | 3.3% | −9.4 |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | 18.5% | +32.8 |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | 4.5% | −27.6 |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | 105.5% | +87.8 |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | 12.7% | +8.7 |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -14.2% | −45.9 |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | 32.1% | +6.7 |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | 17.6% | −3.3 |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | 4.0% | −29.9 |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | 31.7% | +42.6 |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | 25.4% | −7.8 |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | 21.0% | −12.5 |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | 33.9% | +19.6 |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -11.0% | −29.9 |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | 33.3% | +70.1 |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | 33.5% | +68.0 |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | 14.3% | +6.0 |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | 18.9% | +217.2 |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -36.8% | +50.2 |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -34.4% | +155.1 |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | 8.3% | +86.2 |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -198.2% | −21.1 |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -87.0% | −67.7 |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -189.5% | −301.3 |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -77.9% | +49.5 |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -177.1% | +58.9 |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -19.3% | −90.8 |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | 111.8% | −46.0 |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -127.4% | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -236.0% | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | 71.5% | – |
| Q2 FY2017CQ3 2016 | Sep 30, 2016 | 157.8% | – |
See a number that looks wrong?